Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

When telehealth executive Andrew Dudum received a email wishing him a happy Father’s Day last month, he took it as a sign of the strong relationship he’d cultivated with a key partner. He did not see ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Advertising Andrew Dudum, one of the company’s co-founders and its chief executive, started Hims at venture studio Atomic in San Francisco. The startup, now known as Hims & Hers Health Inc., then ...

During the day, Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo Nordisk's (NVO) obesity drug Wegovy. Read more here.

"Canada is a major opportunity to show what affordable, high-quality weight loss care can look like," said Andrew Dudum, co-founder and CEO of Hims & Hers, in a press release.